Hani Malone1, Jingyan Yang2, Dawn L Hershman3, Jason D Wright4, Jeffrey N Bruce1, Alfred I Neugut5. 1. Department of Neurological Surgery, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA. 2. Department of Epidemiology, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA. 3. Department of Epidemiology, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA; Department of Medicine, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA. 4. Department of Epidemiology, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA; Department of Obstetrics & Gynecology, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA. 5. Department of Epidemiology, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA; Department of Medicine, College of Physicians & Surgeons and the Mailman School of Public Health, Columbia University, New York, New York, USA. Electronic address: ain1@cumc.columbia.edu.
Abstract
BACKGROUND: Data from single-institution studies suggest that perioperative complication rates after stereotactic needle brain biopsies range from 6% to 12%, with permanent morbidity and mortality ranging from 3.1% to 6.4% and 0% to 1.7%, respectively. However, no population-level data are available. We conducted a population-based analysis to study complications after needle brain biopsy. METHODS: We analyzed patients recorded in the Nationwide Inpatient Sample who underwent stereotactic needle brain biopsy for neoplastic lesions between 2006 and 2012. A multivariate logistic model was used to identify factors associated with complications. RESULTS: We identified 7514 patients who underwent biopsy for various intracranial pathologies, including primary malignant neoplasm (52.3%), unspecified neoplasm (17.9%), metastasis (9.7%), meningioma (1.5%), radiation necrosis (0.8%), lymphoma (0.5%), and pineal region neoplasm (0.3%). Intracranial hemorrhage was the most frequent complication (5.8%). Other complications, including operative infection (0.1%) and wound breakdown (0.2%), were rare. Multivariate logistic regression analysis revealed that hemorrhage is associated with older age (reference <40 years; 40-59 years, odds ratio [OR] 2.26, 95% confidence interval [CI] 1.51-3.38; ≥60 years, OR 1.90, 95% CI 1.22-2.97), hydrocephalus (OR 3.02, 95% CI 2.20-4.14), and cerebral edema (OR 2.16, 95% CI 1.72-2.72). Hemorrhage is less likely when taking a biopsy from a primary malignant neoplasm (OR 0.73, 95% CI 0.59-0.90). Overall inpatient mortality after biopsy was 2.8%. Patients with intracranial hemorrhage were significantly more likely than patients without hemorrhage to die in the hospital (12.8% vs. 2.2%, P < 0.001) or be discharged to a rehabilitation/nursing facility (45.2% vs. 23.1%, P < 0.001). CONCLUSIONS: Intracranial hemorrhage is the most frequent complication associated with needle brain biopsy and is associated with inpatient mortality and hospital disposition. Other complications are rare.
BACKGROUND: Data from single-institution studies suggest that perioperative complication rates after stereotactic needle brain biopsies range from 6% to 12%, with permanent morbidity and mortality ranging from 3.1% to 6.4% and 0% to 1.7%, respectively. However, no population-level data are available. We conducted a population-based analysis to study complications after needle brain biopsy. METHODS: We analyzed patients recorded in the Nationwide Inpatient Sample who underwent stereotactic needle brain biopsy for neoplastic lesions between 2006 and 2012. A multivariate logistic model was used to identify factors associated with complications. RESULTS: We identified 7514 patients who underwent biopsy for various intracranial pathologies, including primary malignant neoplasm (52.3%), unspecifiedneoplasm (17.9%), metastasis (9.7%), meningioma (1.5%), radiation necrosis (0.8%), lymphoma (0.5%), and pineal region neoplasm (0.3%). Intracranial hemorrhage was the most frequent complication (5.8%). Other complications, including operative infection (0.1%) and wound breakdown (0.2%), were rare. Multivariate logistic regression analysis revealed that hemorrhage is associated with older age (reference <40 years; 40-59 years, odds ratio [OR] 2.26, 95% confidence interval [CI] 1.51-3.38; ≥60 years, OR 1.90, 95% CI 1.22-2.97), hydrocephalus (OR 3.02, 95% CI 2.20-4.14), and cerebral edema (OR 2.16, 95% CI 1.72-2.72). Hemorrhage is less likely when taking a biopsy from a primary malignant neoplasm (OR 0.73, 95% CI 0.59-0.90). Overall inpatient mortality after biopsy was 2.8%. Patients with intracranial hemorrhage were significantly more likely than patients without hemorrhage to die in the hospital (12.8% vs. 2.2%, P < 0.001) or be discharged to a rehabilitation/nursing facility (45.2% vs. 23.1%, P < 0.001). CONCLUSIONS:Intracranial hemorrhage is the most frequent complication associated with needle brain biopsy and is associated with inpatient mortality and hospital disposition. Other complications are rare.
Authors: Daniel G Eichberg; Long Di; Ashish H Shah; Evan M Luther; Christina Jackson; Lina Marenco-Hillembrand; Kaisorn L Chaichana; Michael E Ivan; Robert M Starke; Ricardo J Komotar Journal: J Neurooncol Date: 2020-06-18 Impact factor: 4.130
Authors: Neda Haj-Hosseini; Johan C O Richter; Peter Milos; Martin Hallbeck; Karin Wårdell Journal: Biomed Opt Express Date: 2018-04-20 Impact factor: 3.732